Expression of DNA topoisomerases in chronic proliferative kidney disease.
BACKGROUND
Circulating autoantibodies to human topoisomerases have been reported in glomerular kidney disease associated with scleroderma and systemic lupus erythematosus. However, limited information is available about the expression of topoisomerases in the kidney under normal and pathological conditions.


METHODS
The expression of DNA topoisomerases I and IIalpha was studied by immunohistochemistry on archival biopsies from 70 patients with chronic renal diseases. Normal kidney tissue was examined for comparison. Topoisomerase I was detected by means of monoclonal antibody (mAb) C21, and topoisomerase IIalpha was detected by means of mAb Ki-S4. In addition, mAb Ki-M1p was used to assess the density of monocytic infiltrates. All parameters were assessed in a semiquantitative manner.


RESULTS
Glomerular topoisomerase IIalpha levels were increased in mesangial proliferative glomerulonephritis (MPGN), rapidly progressive glomerulonephritis (RPGN), and lupus nephritis (LN) and were reduced in membranous glomerulonephritis (MGN), chronic transplant nephropathy (CTN), and tubulointerstitial nephritis (TIN). Tubular epithelia displayed high topoisomerase IIalpha levels in mesangiocapillary glomerulonephritis (MCGN), RPGN, TIN, miscellaneous entities (MISC) and LN, and displayed low levels in MPGN and CTN. Topoisomerase I expression was high in the glomeruli of focal segmental glomerulosclerosis (FSGS), MCGN, and RPGN and was extreme in LN, whereas it was strikingly diminished in the glomeruli of MGN, CTN, and TIN. Almost all conditions displayed lower tubular topoisomerase I levels than normal kidney, except for LN, in which the enzyme content was markedly increased. Increased glomerular monocytic infiltrates were found in FSGS, MCGN, RPGN, TIN, and LN, and tubulointerstitial Ki-M1p+ cells were seen at high numbers in MCGN, RPGN, TIN, MISC, and LN. The expression of the topoisomerases I and IIalpha was significantly correlated; also, topoisomerases showed a positive association with the density of monocytic infiltrates. The parameter profiles exhibited significant differences between distinct types of chronic renal disease.


CONCLUSIONS
Topoisomerase IIalpha expression is tightly linked to cell cycling, and topoisomerase I is likely a reflection of gene transcription. Rapidly progressing glomerular disease therefore appears to be accompanied by active mesangial cell proliferation and increased metabolic activity in glomerular cells. The correlation with inflammatory infiltrates is likely to reflect a positive feedback mechanism involving cytokines, growth factors, and adhesion molecules. Assessment of topoisomerases may therefore be of diagnostic help and might allow prognostic predictions. Provided that our observations are supported by clinicopathological follow-up studies, one might envisage the use of topoisomerase inhibitors in the therapy of chronic proliferative renal disease refractory to current treatment protocols.
Ivanova
L V
LV
Moscow Sechenov Medical Academy, Moscow, Russia.
Rudolph
P
P
Kellner
U
U
Jürgensen
A
A
Tareeva
I E
IE
Alm
P
P
Proppe
D
D
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D001706:Biopsy; D002455:Cell Division; D004264:DNA Topoisomerases, Type I / Q000032:analysis / Q000235:genetics / Q000276:immunology; D004250:DNA Topoisomerases, Type II / Q000032:analysis / Q000235:genetics* / Q000276:immunology; D004268:DNA-Binding Proteins; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007527:Isoenzymes / Q000032:analysis / Q000235:genetics* / Q000276:immunology; D007676:Kidney Failure, Chronic / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology; D007678:Kidney Glomerulus / Q000201:enzymology / Q000473:pathology; D008181:Lupus Nephritis / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology*; D009000:Monocytes / Q000276:immunology; D009395:Nephritis, Interstitial / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology*; D012595:Scleroderma, Systemic / Q000201:enzymology / Q000473:pathology / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II